Literature DB >> 10733593

Mesothelin is not required for normal mouse development or reproduction.

T K Bera1, I Pastan.   

Abstract

Mesothelin is a glycosylphosphatidylinositol-linked glycoprotein highly expressed in mesothelial cells, mesotheliomas, and ovarian cancer, but the biological function(s) of the protein is not known. We have analyzed the expression of the mouse mesothelin gene in different developmental stages and in various adult tissues by Northern hybridization. The 2.5-kb mesothelin transcript was detected in the mRNA of E 7.0, E 15.0, and E 17.0 stages of mouse development. In adult tissues the mesothelin gene was expressed in lung, heart, spleen, liver, kidney, and testis. To directly assess the function of the mesothelin in vivo, we generated mutant mice in which the mesothelin gene was inactivated by replacing it with the neomycin resistance gene. In homozygous mutant mice neither mesothelin mRNA nor the protein product was detected. Null mutant mice were obtained in accordance with Mendelian laws, and both males and females produced offspring normally. No anatomical or histological abnormalities were detected in any tissues where mesothelin was reportedly expressed in wild-type mice. Our results demonstrate that mesothelin function is not essential for growth or reproduction in mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733593      PMCID: PMC85523          DOI: 10.1128/MCB.20.8.2902-2906.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  9 in total

1.  Simplified mammalian DNA isolation procedure.

Authors:  P W Laird; A Zijderveld; K Linders; M A Rudnicki; R Jaenisch; A Berns
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

2.  Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma.

Authors:  K Chang; L H Pai; H Pass; H W Pogrebniak; M S Tsao; I Pastan; M C Willingham
Journal:  Am J Surg Pathol       Date:  1992-03       Impact factor: 6.394

3.  Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface.

Authors:  M L Dustin; P Selvaraj; R J Mattaliano; T A Springer
Journal:  Nature       Date:  1987 Oct 29-Nov 4       Impact factor: 49.962

4.  Tissue-specific alternative splicing of the CSE1L/CAS (cellular apoptosis susceptibility) gene.

Authors:  U Brinkmann; E Brinkmann; T K Bera; A Wellmann; I Pastan
Journal:  Genomics       Date:  1999-05-15       Impact factor: 5.736

5.  GPI-anchored cell-surface molecules complexed to protein tyrosine kinases.

Authors:  I Stefanová; V Horejsí; I J Ansotegui; W Knapp; H Stockinger
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

6.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

7.  A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5.

Authors:  N Yamaguchi; K Hattori; M Oh-eda; T Kojima; N Imai; N Ochi
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

8.  Molecular cloning and expression of megakaryocyte potentiating factor cDNA.

Authors:  T Kojima; M Oh-eda; K Hattori; Y Taniguchi; M Tamura; N Ochi; N Yamaguchi
Journal:  J Biol Chem       Date:  1995-09-15       Impact factor: 5.157

9.  Role of B61, the ligand for the Eck receptor tyrosine kinase, in TNF-alpha-induced angiogenesis.

Authors:  A Pandey; H Shao; R M Marks; P J Polverini; V M Dixit
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

  9 in total
  108 in total

1.  Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Authors:  Raffit Hassan; Steven J Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J Kelly; Charles Schweizer; Susan Weil; Daniel Laheru
Journal:  Clin Cancer Res       Date:  2010-10-29       Impact factor: 12.531

Review 2.  Novel systemic therapy against malignant pleural mesothelioma.

Authors:  Michael R Mancuso; Joel W Neal
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Authors:  Federico Nichetti; Antonio Marra; Francesca Corti; Alessandro Guidi; Alessandra Raimondi; Natalie Prinzi; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

4.  Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.

Authors:  Prasad S Adusumilli
Journal:  Cancer       Date:  2014-07-02       Impact factor: 6.860

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Authors:  Prince Awuah; Tapan K Bera; Messan Folivi; Oleg Chertov; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

7.  Mesothelin expression in the leptomeninges and meningiomas.

Authors:  Mahlon D Johnson; Fran Vito; Mary J O'Connell
Journal:  J Histochem Cytochem       Date:  2008-03-17       Impact factor: 2.479

8.  High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma.

Authors:  W-F Cheng; C-Y Huang; M-C Chang; Y-H Hu; Y-C Chiang; Y-L Chen; C-Y Hsieh; C-A Chen
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

9.  Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats.

Authors:  Bangalore K Sathyanarayana; Yoonsoo Hahn; Manish S Patankar; Ira Pastan; Byungkook Lee
Journal:  BMC Struct Biol       Date:  2009-01-07

10.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.